Latest Breaking News On - Ibrahim aldoss - Page 1 : comparemela.com

Dr Aldoss on Responses With WU-CART-007 After Enhanced Lymphodepletion in R/R T-ALL/LBL

Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.

Dr Aldoss on the Mechanism of Action of Ponatinib in Ph+ ALL

Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL.

Revumenib Led to Durable Remission in Patients with Acute Leukemia, According to Expert

In the Augment-101 phase 2 study, 63% of patients experienced overall response rate with revumenib.

Asparaginase Hypersensitivity: Immune Reactions of a Key Tool Against ALL

Oncology nurses must be on the look-out for immune hypersensitivity reactions and other serious toxicities in patients receiving L-asparaginase.

Syndax Pharmaceuticals (SNDX) Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib